Maryland State Retirement & Pension System Has $1.63 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Maryland State Retirement & Pension System reduced its stake in Alnylam Pharmaceuticals by 13.9% in Q1, resulting in $1.63 million worth of holdings.
• CEO Yvonne Greenstreet sold 19,297 shares, reflecting a 28.28% decrease in her ownership, with the sale totaling approximately $5.9 million.
• Alnylam Pharmaceuticals reported a positive earnings per share of $0.32, exceeding analysts' expectations, with a revenue increase of 17.3% compared to the previous year.

Maryland State Retirement & Pension System lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,021 shares of the biopharmaceutical company's stock after selling 969 shares during the period. Maryland State Retirement & Pension System's holdings in Alnylam Pharmaceuticals were worth $1,626,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in Alnylam Pharmaceuticals during the 1st quarter worth about $275,000. GAMMA Investing LLC lifted its position in Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock worth $166,000 after buying an additional 77 shares in the last quarter. Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $243,000. Finally, Silvercrest Asset Management Group LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $1,151,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,978,088. This represents a 28.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Up 0.9%

Shares of NASDAQ ALNY opened at $438.93 on Friday. The stock has a market cap of $57.53 billion, a P/E ratio of -177.70 and a beta of 0.25. The firm has a 50 day moving average price of $331.79 and a 200 day moving average price of $284.83. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.98 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $439.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. The business had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. During the same period in the prior year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Chardan Capital upped their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Piper Sandler upped their price target on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Raymond James Financial assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They set an "outperform" rating and a $370.00 price target on the stock. Finally, BMO Capital Markets upped their price target on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 24th. Four analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $403.92.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.